Legend Biotech
LEGN
15.25
-0.85
-5.28%
Legend Biotech
US · LEGN
#2374 by market cap
Listed 2020
15.25
-0.85
-5.28%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 10 in the most recent period (2026/Q3).
- Total institutional ownership fell 3.9 percentage points.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 103.67% -3.87pp
- Institutions
- 271 -10
- As of
- 2026/Q3 vs. prior period
Holder types
Public Company47.96%
Mutual Fund27.67%
Hedge Fund15.90%
Private Company8.28%
VC/PE Fund3.51%
Government Pension Fund0.21%
Individual/Insider0.12%
Insurance Company0.10%
Other46.99%
Top holders as of 2026-02-15
Genscript Biotech Corporation
44.98% · 87.25M sh
FMR
12.32% · 23.91M sh
AquaPoint L.P.
7.80% · 15.14M sh
Deerfield Management Company, L.P.
4.20% · 8.14M sh
Montanova Capital, LLC
3.64% · 7.07M sh
Hillhouse Capital Management, Ltd.
3.09% · 5.98M sh
BlackRock
2.63% · 5.09M sh
Westfield Capital Management Company, L.P.
2.28% · 4.43M sh
Kynam Capital Management, LP
1.55% · 3.00M sh
The Goldman Sachs Group, Inc.
1.87% · 3.63M sh
Point72 Asset Management, L.P.
1.59% · 3.08M sh
Assenagon Asset Management S.A.
0.99% · 1.92M sh
Artisan Partners Limited Partnership
0.80% · 1.56M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
49 filings tracked · 0 buys · 41 sells
| Name | Role | Stake |
|---|---|---|
| Ying Huang | Former Chief Executive Officer | 0.06% |
| Xiaohui Ji | Independent Director | 0.01% |
| Patrick Casey | Independent Director | 0.01% |
| Li Mao | Independent Director | 0.01% |
| Tomas Heyman | Independent Director | 0.01% |
| Corazon Sanders | Independent Director | 0.01% |
| Gareth Kung | Independent Director | -- |
| Jessie Yeung | Former Vice President of Finance, Investor & Public Relations | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-03-25 | Ying Huang | Former Chief Executive Officer | Intent to Sell (Form 144) | -4,968 | $17.54 |
| 2026-03-25 | Jessie Yeung | Former Vice President of Finance, Investor & Public Relations | Intent to Sell (Form 144) | -1,862 | $17.54 |
| 2026-03-17 | Corazon Sanders | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Ying Huang | Former Chief Executive Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Gareth Kung | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Xiaohui Ji | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Tomas Heyman | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Patrick Casey | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Li Mao | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2025-12-25 | Ying Huang | Former Chief Executive Officer | Intent to Sell (Form 144) | -64,339 | $22.52 |
| 2025-12-23 | Corazon Sanders | Independent Director | Intent to Sell (Form 144) | -969 | $22.77 |
| 2025-12-23 | Ying Huang | Former Chief Executive Officer | Intent to Sell (Form 144) | -61,467 | $22.95 |
| 2025-11-16 | GenScript Corporation | -- | Intent to Sell (Form 144) | -203,586 | $30.29 |
| 2025-09-25 | Patrick Casey | Independent Director | Intent to Sell (Form 144) | -1,000 | $33.29 |
| 2025-09-23 | Ying Huang | Former Chief Executive Officer | Intent to Sell (Form 144) | -1,370 | $33.00 |
| 2025-09-22 | Corazon Sanders | Independent Director | Intent to Sell (Form 144) | -307 | $34.00 |
| 2025-09-22 | Ying Huang | Former Chief Executive Officer | Intent to Sell (Form 144) | -1,357 | $33.98 |
| 2025-09-22 | Jessie Yeung | Former Vice President of Finance, Investor & Public Relations | Intent to Sell (Form 144) | -474 | $33.98 |
| 2025-07-22 | Ying Huang | Former Chief Executive Officer | Intent to Sell (Form 144) | -15,291 | $45.04 |
| 2025-06-25 | Patrick Casey | Independent Director | Intent to Sell (Form 144) | -1,000 | $33.23 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 20:02:40 · For reference only, not investment advice and not tailored to your situation.
Legend Biotech discussion 0 comments